-
公开(公告)号:US20180354995A1
公开(公告)日:2018-12-13
申请号:US16017251
申请日:2018-06-25
CPC分类号: C07K14/195 , A61K38/164 , A61K39/0013 , A61K39/02 , A61K39/39 , A61K45/06 , A61K2039/55505 , A61K2039/55516 , A61K2039/55583 , A61K2039/55594 , A61K2039/57 , A61K2039/575 , C07K2319/00 , C07K2319/21 , Y02A50/388 , Y02A50/39 , Y02A50/466 , Y02A50/484
摘要: The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.
-
2.
公开(公告)号:US20180333475A1
公开(公告)日:2018-11-22
申请号:US15539774
申请日:2015-12-23
申请人: Conjugon, Inc.
CPC分类号: A61K39/02 , A61K9/0019 , A61K9/19 , A61K35/74 , A61K39/05 , A61K39/104 , C12N1/04 , C12N1/20 , C12N15/00 , C12N15/70 , C12N15/74 , Y02A50/403 , Y02A50/478 , Y02A50/48
摘要: The present invention relates to the field of bacteriology. In particular, the invention relates to methods and compositions for treatment and prevention of infection in wounds, and methods for producing and storing bacterial donor organisms for conjugation-based antibacterial agents. The present invention relates to the field of bacteriology and pharmacology. In particular, the invention relates to novel compositions (e.g., antimicrobial agents) and methods of using the same for treating tissue (e.g., lesions of the skin and other soft tissues) comprising the killing or altering (e.g., inhibiting) growth and virulence of populations of microorganisms.
-
3.
公开(公告)号:US20180311341A1
公开(公告)日:2018-11-01
申请号:US15770869
申请日:2016-10-25
发明人: Hiroaki Suzuki , Kenta JOUNAI , Daisuke FUJIWARA
IPC分类号: A61K39/39 , A61K9/00 , A61K35/747 , A61K39/145 , C12N7/00 , A23L33/135
CPC分类号: A23L33/10 , A61K35/747 , A61K39/00 , A61K39/02 , A61K39/12 , A61K39/39 , C12N1/20 , Y02A50/403
摘要: Provided are a composition and a food or drink, having the effect of enhancing an immune response to an antigen, which is administered by another route such as subcutaneous injection, by orally administering to a subject, lactic acid bacteria, a culture thereof, a treated product thereof, or a composition comprising the same.An oral ingestion composition, which comprises a lactic acid bacterium strain that is Lactococcus lactis subsp. lactis enhancing the proliferation of cytotoxic T lymphocytes (CTL) and the generation of antibodies, or a culture or treated product thereof, and is used in combination with an antigen as a vaccine, wherein the oral ingestion composition is for use in enhancing the proliferation of cytotoxic T lymphocytes (CTL) specific to the antigen and the generation of antibodies specific to the antigen.
-
公开(公告)号:US10059749B2
公开(公告)日:2018-08-28
申请号:US15920924
申请日:2018-03-14
发明人: Jiunn-Horng Lin , Jyh-Perng Wang , Zeng-Weng Chen , Chien-Yu Fang , Ming-Wei Hsieh , Ping-Cheng Yang
CPC分类号: C07K14/30 , A61K38/164 , A61K39/02 , C12N15/70
摘要: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.
-
公开(公告)号:US20180208629A1
公开(公告)日:2018-07-26
申请号:US15920924
申请日:2018-03-14
发明人: JIUNN-HORNG LIN , JYH-PERNG WANG , ZENG-WENG CHEN , CHIEN-YU FANG , MING-WEI HSIEH , PING-CHENG YANG
CPC分类号: C07K14/30 , A61K38/164 , A61K39/02 , C12N15/70
摘要: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.
-
公开(公告)号:US20180169205A1
公开(公告)日:2018-06-21
申请号:US15737058
申请日:2016-08-06
发明人: David D. Lo , Kaila M. Bennett
CPC分类号: A61K39/02 , A61K39/12 , A61K39/39 , A61K2039/54 , A61K2039/545 , A61K2039/55516 , A61K2039/575 , A61K2039/6068 , A61K2039/645 , A61K2039/70 , C07K2/00 , C12N2770/24134
摘要: A method of immunizing a subject. The method includes administering to the subject an immunogenic amount of a filament including one or more hybrid flagellin proteins, each hybrid protein including a heterologous polypeptide antigen and a portion of a FliC flagellin protein. As a result of the administration, a TI immune response to the polypeptide antigen can be produced in the subject.
-
公开(公告)号:US09951109B2
公开(公告)日:2018-04-24
申请号:US15032758
申请日:2013-11-21
发明人: Jiunn-Horng Lin , Jyh-Perng Wang , Zeng-Weng Chen , Chien-Yu Fang , Ming-Wei Hsieh , Ping-Cheng Yang
CPC分类号: C07K14/30 , A61K38/164 , A61K39/02 , C12N15/70
摘要: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.
-
8.
公开(公告)号:US09950055B2
公开(公告)日:2018-04-24
申请号:US14162600
申请日:2014-01-23
申请人: KUROS BIOSCIENCES AG
发明人: Martin F. Bachmann , Tazio Storni , Patrik Maurer , Alain Tissot , Katrin Schwarz , Edwin Meijerink , Gerd Lipowsky , Paul Pumpens , Indulis Cielens , Regina Renhofa
CPC分类号: A61K39/12 , A61K39/00 , A61K39/0011 , A61K39/02 , A61K39/39 , A61K2039/52 , A61K2039/5258 , A61K2039/55555 , A61K2039/55561 , A61K2039/57 , A61K2039/6075 , C07K14/005 , C07K2319/00 , C12N7/00 , C12N2710/22022 , C12N2710/22023 , C12N2730/10122 , C12N2730/10123 , C12N2795/00034 , C12N2795/18122 , Y02A50/412 , Y02A50/467
摘要: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
-
公开(公告)号:US09913887B2
公开(公告)日:2018-03-13
申请号:US14968074
申请日:2015-12-14
发明人: Leonard Weisman , Lingkun Kong
IPC分类号: C07K16/00 , A61K39/02 , C07K16/12 , G01N33/569 , A61K39/00
CPC分类号: A61K39/0208 , A61K39/02 , A61K39/0241 , A61K2039/53 , C07K16/1253 , G01N33/56911 , G01N2333/30 , G01N2469/10
摘要: The present invention encompasses methods and compositions for Ureaplasma infection prevention and/or treatment. In specific cases, the invention concerns vaccines for Ureaplasma, including DNA vaccines. In certain embodiments, the invention regards vaccines directed towards the multiple-banded antigen(s) of Ureaplasma.
-
公开(公告)号:US09895433B2
公开(公告)日:2018-02-20
申请号:US15192757
申请日:2016-06-24
CPC分类号: A61K39/0208 , A61K39/00 , A61K39/02 , A61K2039/52 , A61K2039/522 , A61K2039/58 , A61K2039/585
摘要: Mutant Listeria bacteria that modulate interferon-β production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a TetR gene, a LadR gene, a VirR gene, a MarR gene a MdrL gene, a MdrT gene and a MdrM gene. The subject bacteria find use in a variety of applications, where representative applications of interest include, but are not limited to: (a) use of the subject bacteria as adjuvants; (b) use of the subject bacteria as delivery vectors for introducing macromolecules into a cell; (c) use of the subject bacteria as vaccines for eliciting or boosting a cellular immune response; etc.
-
-
-
-
-
-
-
-
-